ORIC ▼ -0.1% - ORIC Pharmaceuticals, Inc.
$ORIC - ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
23-OCT-2026 03:15 AM ET
Share this post
More filings for $ORIC
ORIC ▼ -0.1% - ORIC Pharmaceuticals, Inc.Oct 23, 2026ORIC ▲ +1.1% - ORIC Pharmaceuticals, Inc.Oct 19, 2026ORIC ▲ +2.4% - ORIC Pharmaceuticals, Inc.Oct 5, 2026ORIC ▲ +1.9% - ORIC Pharmaceuticals, Inc.Sep 2, 2026
View full $ORIC filing history →💬 Comments
Loading comments…
Leave a comment